InvestorsHub Logo
Followers 8
Posts 443
Boards Moderated 0
Alias Born 03/25/2016

Re: gestalt2 post# 23189

Monday, 06/11/2018 10:26:58 AM

Monday, June 11, 2018 10:26:58 AM

Post# of 232916
Gestalt, here is something new from the ASM Poster - "A roll-over study, PRO 140 CD02-Extension, was designed to extend a subject's access to PRO 140 treatment when, in the opinion of the treating physician, PRO 140 was required to form a viable suppressive regimen."

Of critical significance is that...."To date, 35 subjects have entered the extension study."




Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News